Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Transaction Price: $45.973 per ADS.
- Transaction Date: April 13, 2012.
- Transaction Type: Increase in interests via dividend re-investment.
Material Changes
The filing details specific increases in ADS holdings for the following individuals following the dividend paid on April 12, 2012:
- Dr M M Slaoui: 634.044 ADSs.
- Dr K Slaoui (Connected Person): 18.915 ADSs.
- Mr W C Louv (Connected Person): 276.405 ADSs.
- Dr D Pulman: 398.265 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Checklist
- Verify the total number of ADSs held by the named directors post-transaction.
- Confirm the dividend re-investment plan terms applicable to the April 12, 2012 dividend.
- Check the market price of GSK ADSs on April 13, 2012, to validate the reported transaction price of $45.973.